Arog Pharmaceuticals Announces Oral Presentation on Crenolanib at the 2017 American Society of Hematology Annual Meeting

DALLAS, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that it will present data on its lead product candidate, crenolanib, at the 59th American Society of Hematology (ASH) Annual Meeting, taking place December 9-12, 2017 in Atlanta, GA. Crenolanib continues to demonstrate best-in-class properties in the treatment of acute myeloid leukemia (AML) with FLT3 mutations.

Oral Presentation, Abstract #566

Title: Low Relapse Rate in Younger Patients ≤ 60 Years Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and Cytarabine/Anthracycline Chemotherapy

Presenter: Eunice S. Wang, MD

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Risk Factors and Response-Adapted Personalized Medicine

Date & Time: 7:15 AM EST, Monday, December 11, 2017
Location: Georgia World Congress Center, Building B, Level 5, Murphy BR 1-2

About Arog Pharmaceuticals, Inc.

Arog Pharmaceuticals is a private, clinical-stage biopharmaceutical company that has leveraged its platform of benzimidazole derivatives to develop a robust drug pipeline of orally available, potent, and selective small molecule type I tyrosine kinase inhibitors (TKIs).  Arog is undergoing preparations for pivotal, randomized Phase III trials of its lead molecule, crenolanib.  For more information, please visit the company’s website,

About Crenolanib 

Arog’s lead molecule, crenolanib, is a type I TKI that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTKs), FLT3 and PDGFRα/β.  Crenolanib has an established record of patient safety and has been used to treat over 350 patients. Crenolanib has been clinically investigated in combination with standard induction or salvage chemotherapy in patients with FLT3 mutant acute myeloid leukemia (AML). Additionally, crenolanib is being clinically investigated in solid tumors, including gastrointestinal stromal tumors (GIST) harboring the PDGFRα D842V mutation.

About FLT3 

FLT3 is a class III RTK, and its signaling is considered important for the normal development of hematopoietic stem cells and progenitor cells.  The FLT3 gene is one of the most frequently mutated genes (~30%) in AML.  One such mutation, internal tandem duplications of FLT3 (FLT3-ITD), is a prognostic indicator associated with adverse disease outcome.

About PDGFRα D842V Mutations  

PDGFRAD842V is a gain-of-function mutation that constitutively activates PDGFRA downstream signaling pathway. D842V is the most common PDGFRA mutation and is well-known to be resistant to imatinib and sunitinib.


The Trout Group
Peter Rahmer
(646) 378-2973